American Society of Hematology (ASH) Annual Meeting, December 2017
Abstracts from the Multiple Myeloma Program at Mount Sinai

ASH annual meeting abstracts selected for oral and poster presentations represent important, novel research in the field and are considered the best of the thousands submitted for the ASH annual meeting.


Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma https://ash.confex.com/ash/2017/webprogram/Paper107293.html


MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA https://ash.confex.com/ash/2017/webprogram/Paper105762.html

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2017/webprogram/Paper100918.html

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study https://ash.confex.com/ash/2017/webprogram/Paper107861.html

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study https://ash.confex.com/ash/2017/webprogram/Paper104318.html

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience https://ash.confex.com/ash/2017/webprogram/Paper107524.html